Literature DB >> 9557659

Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro.

P R Harrigan1, S Bloor, B A Larder.   

Abstract

Replication of mixtures of two or more human immunodeficiency virus type 1 (HIV-1) variants would be expected to result in the eventual selection of the fittest virus due to Darwinian competition among the variants. The relative proportions of known HIV-1 variants (which may differ only by a single nucleotide from a standard "wild-type" virus, HIV-1HXB2) in mixed viral cultures were quantified by analysis of automated sequence signals of reverse transcriptase PCR products. With this method, the relative levels of replicative fitness of several zidovudine (3'-azidothymidine)-resistant HIV-1HXB2 variants were estimated under controlled in vitro conditions by measuring the rate of change in the proportions of viral variants as they replicated in cell cultures both in the presence and in the absence of drug selection pressure. These variants were engineered to contain commonly observed zidovudine resistance mutations in the HIV-1 reverse transcriptase (M41L, K70R, T215Y, and M41L+T215Y). In the absence of zidovudine, all variants tested displayed reduced replicative fitness compared to wild-type HIV-1HXB2. The order of relative fitness was wild type > K70R >> T215Y = M41L+T215Y > M41L. Mixed cultures in the presence of zidovudine showed a dose-dependent selection pressure against the wild-type virus which varied according to the resistance profile of each virus. The information gathered from this approach provides insight into competition among multiple HIV-1 variants, which likely occurs in vivo with drug selection pressure, and may be applicable in more complex mathematical models for predicting the emergence of HIV-1 variants after the initiation of antiretroviral therapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9557659      PMCID: PMC109599          DOI: 10.1128/JVI.72.5.3773-3778.1998

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  28 in total

Review 1.  Clinical significance of drug resistance in HIV-1 infection.

Authors:  D R Kuritzkes
Journal:  AIDS       Date:  1996-12       Impact factor: 4.177

2.  Reverse transcriptase fidelity and HIV-1 variation.

Authors:  J Balzarini; H Pelemans; E De Clercq; A Karlsson; J P Kleim
Journal:  Science       Date:  1997-01-10       Impact factor: 47.728

3.  HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.

Authors:  B A Larder; G Darby; D D Richman
Journal:  Science       Date:  1989-03-31       Impact factor: 47.728

Review 4.  Human immunodeficiency virus type 1 protease inhibitors.

Authors:  C K McDonald; D R Kuritzkes
Journal:  Arch Intern Med       Date:  1997-05-12

5.  An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3'-azido-3'-deoxythymidine.

Authors:  D J Hooker; G Tachedjian; A E Solomon; A D Gurusinghe; S Land; C Birch; J L Anderson; B M Roy; E Arnold; N J Deacon
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

6.  HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time.

Authors:  A S Perelson; A U Neumann; M Markowitz; J M Leonard; D D Ho
Journal:  Science       Date:  1996-03-15       Impact factor: 47.728

7.  Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).

Authors:  B A Larder; S D Kemp
Journal:  Science       Date:  1989-12-01       Impact factor: 47.728

8.  Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215.

Authors:  J Goudsmit; A de Ronde; E de Rooij; R de Boer
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

9.  Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapy. Canadian Zidovudine Multi-Centre Study Group.

Authors:  R Rooke; M Tremblay; H Soudeyns; L DeStephano; X J Yao; M Fanning; J S Montaner; M O'Shaughnessy; K Gelmon; C Tsoukas
Journal:  AIDS       Date:  1989-07       Impact factor: 4.177

10.  Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility.

Authors:  P R Harrigan; I Kinghorn; S Bloor; S D Kemp; I Nájera; A Kohli; B A Larder
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

View more
  68 in total

1.  Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: a comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Val.

Authors:  P L Sharma; C S Crumpacker
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

2.  Estimating relative fitness in viral competition experiments.

Authors:  A F Marée; W Keulen; C A Boucher; R J De Boer
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

Review 3.  A fossil record of zidovudine resistance in transmitted isolates of HIV-1.

Authors:  D R Kuritzkes
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

4.  Immunogenicity of mutations induced by nucleoside reverse transcriptase inhibitors for human immunodeficiency virus type 1-specific cytotoxic T cells.

Authors:  A Samri; G Haas; J Duntze; J M Bouley; V Calvez; C Katlama; B Autran
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

5.  Antiretroviral Drug Resistance in HIV-1.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-08       Impact factor: 3.725

6.  Procedures for reliable estimation of viral fitness from time-series data.

Authors:  Sebastian Bonhoeffer; Andrew D Barbour; Rob J De Boer
Journal:  Proc Biol Sci       Date:  2002-09-22       Impact factor: 5.349

7.  Fluorescent dye terminator sequencing methods for quantitative determination of replication fitness of human immunodeficiency virus type 1 containing the codon 74 and 184 mutations in reverse transcriptase.

Authors:  Viktoria Nurpeisov; Selwyn J Hurwitz; Prem L Sharma
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

8.  Impaired replication capacity of acute/early viruses in persons who become HIV controllers.

Authors:  Toshiyuki Miura; Zabrina L Brumme; Mark A Brockman; Pamela Rosato; Jennifer Sela; Chanson J Brumme; Florencia Pereyra; Daniel E Kaufmann; Alicja Trocha; Brian L Block; Eric S Daar; Elizabeth Connick; Heiko Jessen; Anthony D Kelleher; Eric Rosenberg; Martin Markowitz; Kim Schafer; Florin Vaida; Aikichi Iwamoto; Susan Little; Bruce D Walker
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

9.  Evaluation of a multiple-cycle, recombinant virus, growth competition assay that uses flow cytometry to measure replication efficiency of human immunodeficiency virus type 1 in cell culture.

Authors:  Carrie Dykes; Jiong Wang; Xia Jin; Vicente Planelles; Dong Sung An; Amanda Tallo; Yangxin Huang; Hulin Wu; Lisa M Demeter
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

10.  Functional correlates of insertion mutations in the protease gene of human immunodeficiency virus type 1 isolates from patients.

Authors:  E Y Kim; M A Winters; R M Kagan; T C Merigan
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.